72 72 van't Hof AWJ, Berg J ten, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST‐elevation myocardial infarction undergoing primary angioplasty (On‐TIME 2): a multicentre, double‐blind, randomised controlled trial. The Lancet 2008; 372:537–46.
73 73 Berg JM ten, van 't Hof AWJ, Dill T, et al. Effect of early, pre‐hospital initiation of high bolus dose tirofiban in patients with ST‐segment elevation myocardial infarction on short‐ and long‐term clinical outcome. J Am Coll Cardiol 2010; 55:2446–55.
74 74 Dannenberg L, Wolff G, Naguib D, et al. Safety and efficacy of Tirofiban in STEMI‐patients. Int J Cardiol 2019; 274:35–9.
75 75 Zhang Z, Li W, Wu W, et al. Myokardreperfusion mit Tirofibaninjektion via Aspirationskatheter: Wirksamkeit und Sicherheit bei STEMI‐Patienten mit hoher Thrombuslast [Myocardial reperfusion with tirofiban injection via aspiration catheter: Efficacy and safety in STEMI patients with large thrombus burden]. Herz 2020; 45:280–7.
76 76 Gibson CM, Kirtane AJ, Murphy SA, et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST‐segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)‐TIMI 34 trial. Am Heart J 2006; 152:668–75.
77 77 Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST‐segment elevation myocardial infarction: results of the EVA‐AMI Trial. J Am Coll Cardiol 2010; 56:463–9.
78 78 Akerblom A, James SK, Koutouzis M, et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol 2010; 56:470–5.
79 79 Savonitto S, De Luca G, Goldstein P, et al. Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2017; 6:173–90.
80 80 Schulz S, Richardt G, Laugwitz K‐L, et al. Prasugrel plus bivalirudin vs clopidogrel plus heparin in patients with ST‐segment elevation myocardial infarction. Eur Heart J 2014; 35:2285–94.
81 81 Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med 2017; 377:1132–42.
82 82 Shah R, Jovin IS, Chaudhry A, et al. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheter Cardiovasc Interv 2019; 93:241–7.
83 83 Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel‐eluting stents versus bare‐metal stents in acute myocardial infarction (HORIZONS‐AMI): final 3‐year results from a multicentre, randomised controlled trial. The Lancet 2011; 377:2193–204.
84 84 Stone GW, Clayton T, Deliargyris EN, et al. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS‐AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). J Am Coll Cardiol 2014; 63:15–20.
85 85 Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218–30.
86 86 Steg PG, van 't Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369:2207–17.
87 87 Dauerman HL, Frederick PD, Miller D, French WJ. Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction. Coron Artery Dis 2007; 18:141–8.
88 88 Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT‐PPCI): an open‐label, single centre, randomised controlled trial. The Lancet 2014; 384:1849–58.
89 89 Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 2015; 313:1336–46.
90 90 Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med 2015; 373:997–1009.
91 91 Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST‐elevation myocardial infarction: the international randomised open‐label ATOLL trial. The Lancet 2011; 378:693–703.
92 92 Silvain J, Beygui F, Barthélémy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta‐analysis. BMJ 2012; 344:e553.
93 93 Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST‐segment elevation myocardial infarction: the OASIS‐6 randomized trial. JAMA 2006; 295:1519–30.
94 94 Group FTT'C. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. The Lancet 1994; 343:311–22.
95 95 Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317:581–8.
96 96 O'Neill WW, Weintraub R, Grines C, et al. A prospective, placebo‐controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992; 86:1710–6.
97 97 ASSENT‐4 PCI Investigators. Primary versus tenecteplase‐facilitated percutaneous coronary intervention in patients with ST‐segment elevation acute myocardial infarction (ASSENT‐4 PCI): randomised trial. The Lancet 2006; 367:569–78.
98 98 Sutton AGC, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST‐segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004; 44:287–96.
99 99 Gershlick AH, Stephens‐Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005; 353:2758–68.
100 100 Desch S, Eitel I, Rahimi K, et al. Timing of invasive treatment after fibrinolysis in ST elevation myocardial infarction‐‐a meta‐analysis of immediate or early routine versus deferred or ischemia‐guided randomised controlled trials. Heart 2010; 96:1695–702.
101 101 Madan M, Halvorsen S, Di Mario C, et al. Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST‐segment elevation myocardial infarction: a patient‐level analysis of the randomized early routine invasive clinical trials. JACC Cardiovasc Interv 2015; 8:166–74.
102 102 Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142–54.
103 103 GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673–82.
104 104 van de Werf F. Single‐bolus tenecteplase compared with front‐loaded alteplase in acute myocardial infarction: the ASSENT‐2 double‐blind randomised trial. The Lancet 1999; 354:716–22.
105 105 ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group. Randomised Trial of Intervenous Streptokinase, Oral Aspirin, Both, or Neither Among 17,187 Cases of